Literature DB >> 23035058

Fingolimod and multiple sclerosis: four cautionary tales.

Dennis Bourdette, Don Gilden.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23035058     DOI： 10.1212/WNL.0b013e3182735edf

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  19 in total

Review 1.  Current and Emerging Therapies in Multiple Sclerosis: Implications for the Radiologist, Part 1-Mechanisms, Efficacy, and Safety.

Authors:  C McNamara; G Sugrue; B Murray; P J MacMahon
Journal:  AJNR Am J Neuroradiol       Date:  2017-04-13       Impact factor: 3.825

2.  Basis for fluctuations in lymphocyte counts in fingolimod-treated patients with multiple sclerosis.

Authors:  David Henault; Lorna Galleguillos; Craig Moore; Trina Johnson; Amit Bar-Or; Jack Antel
Journal:  Neurology       Date:  2013-10-16       Impact factor: 9.910

3.  Switching therapies in multiple sclerosis.

Authors:  Patricia K Coyle
Journal:  CNS Drugs       Date:  2013-04       Impact factor: 5.749

Review 4.  Safety, tolerability, and efficacy of oral therapies for relapsing-remitting multiple sclerosis.

Authors:  Jiwon Oh; Paul W O'Connor
Journal:  CNS Drugs       Date:  2013-08       Impact factor: 5.749

Review 5.  Vaccines in Multiple Sclerosis.

Authors:  Eric M L Williamson; Salim Chahin; Joseph R Berger
Journal:  Curr Neurol Neurosci Rep       Date:  2016-04       Impact factor: 5.081

Review 6.  Regulation of lymphocyte trafficking in central nervous system autoimmunity.

Authors:  Mohamed Oukka; Estelle Bettelli
Journal:  Curr Opin Immunol       Date:  2018-09-27       Impact factor: 7.486

Review 7.  Infection risk in patients on multiple sclerosis therapeutics.

Authors:  Eric M Williamson; Joseph R Berger
Journal:  CNS Drugs       Date:  2015-03       Impact factor: 5.749

8.  Effects of sphingosine-1-phosphate receptor 1 phosphorylation in response to FTY720 during neuroinflammation.

Authors:  Hsing-Chuan Tsai; Yingxiang Huang; Christopher S Garris; Monica A Moreno; Christina W Griffin; May H Han
Journal:  JCI Insight       Date:  2016-06-16

Review 9.  Targeting cells in motion: migrating toward improved therapies.

Authors:  Jason W Griffith; Andrew D Luster
Journal:  Eur J Immunol       Date:  2013-05-13       Impact factor: 5.532

Review 10.  Defining and scoring response to IFN-β in multiple sclerosis.

Authors:  Maria Pia Sormani; Nicola De Stefano
Journal:  Nat Rev Neurol       Date:  2013-07-30       Impact factor: 42.937
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.